Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BCRX - Biocryst Pharmaceuticals Inc.


IEX Last Trade
8.69
0.060   0.690%

Share volume: 1,743,632
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$8.63
0.06
0.70%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
37%
Profitability 47%
Dept financing 26%
Liquidity 70%
Performance 22%
Company vs Stock growth
vs
Performance
5 Days
7.28%
1 Month
17.43%
3 Months
32.27%
6 Months
52.19%
1 Year
25.22%
2 Year
-37.17%
Key data
Stock price
$8.69
P/E Ratio 
-12.32
DAY RANGE
N/A - N/A
EPS 
-$0.73
52 WEEK RANGE
$4.03 - $8.84
52 WEEK CHANGE
$0.19
MARKET CAP 
1.798 B
YIELD 
N/A
SHARES OUTSTANDING 
206.886 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
BETA 
1.47
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,916,397
AVERAGE 30 VOLUME 
$2,364,928
Company detail
CEO: Jon Stonehouse
Region: US
Website: https://www.biocryst.com/
Employees: 496
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.

Recent news